Adaptive Biotechnologies
ADPT
210 hedge funds and large institutions have $921M invested in Adaptive Biotechnologies in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 68 increasing their positions, 80 reducing their positions, and 28 closing their positions.
321% more call options, than puts
Call options by funds: $2.39M | Put options by funds: $568K
1.69% more ownership
Funds ownership: 93.39% → 95.08% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 226 → 210 (-16)
15% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 80
22% less capital invested
Capital invested by funds: $1.18B → $921M (-$258M)
50% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$9.28M |
| 2 |
AAP
Aristotle Atlantic Partners
Sarasota,
Florida
|
+$8.91M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$7.89M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$7.89M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$6.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.57M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.79M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.33M |
| 4 |
BlackRock
New York
|
-$2.13M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$1.84M |
ADPT Hedge Fund Activity: Q2 2023 in Review
210 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2023, worth a combined $921M — down 22% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ADPT and 14 opened new positions — a net loss of 14 holders — while 80 trimmed existing stakes and 68 added.
The largest buyer was ARK Investment Management, adding an estimated $9.28M. The largest seller was Nuveen, cutting an estimated $3.57M.
- 210 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2023, down from 226 in Q1 2023.
- Funds reported $921M of Adaptive Biotechnologies stock for Q2 2023, down 22% quarter-over-quarter.
- 14 funds opened new Adaptive Biotechnologies positions in Q2 2023 and 28 closed out, a net change of -14 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2023 was ARK Investment Management, an estimated $9.28M added.
- The largest Adaptive Biotechnologies seller in Q2 2023 was Nuveen, an estimated $3.57M sold.
Based on aggregated 13F filings for Q2 2023.